⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplemental Figure 4 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth

Hilary A. Kenny Carman Ka Man Ip Lucy Kelliher Tejas Samantaray Kasjusz Kordylewicz Rachael Hoffmann Sarah Rauch Beatrice Malacrida Sophie L.P. Skingsley Frances R. Balkwill Chiara Battistini Ugo Cavallaro Wolf R. Wiedemeyer Ernst Lengyel

View at Publisher

Ask AI

Bookmark

Share

Key Points

NAVITOCLAX and YM155 effectively inhibit tumor growth in ovarian cancer when combined with carboplatin.
ALDH populations, associated with cancer stem cells, show altered expression in response to the treatment.
The study uses in vitro methods to assess the effects of drug combinations on cancer cell viability.
This approach offers potential new strategies for improving outcomes in ovarian cancer patients.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Combination therapy with navitoclax and ym155 shows effectiveness against ovarian cancer, suggesting new treatment strategies.

Abstract

Stem cell marker expression of ALDH populations

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kenny et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d02cf https://doi.org/10.1158/1535-7163.29759677

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 2 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
2Supplemental Figure 3 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
3Supplemental Figure 1 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
4Supplemental Figure 11 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
5Supplemental Figure 10 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025

More related papers

Supplemental Figure 5 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
Supplemental Figure 9 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025
Supplemental Figure 14 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth2025